Giant cell arteritis: Intensity of the initial systemic inflammatory response and the course of the disease

Clinical and Experimental Rheumatology

Volumn 26, Issue 3 SUPPL. 49, 2008, Pages

  Nesher, Gideon ^a,b   Nesher, Ronit ^c   Mates, Michal ^d,e   Sonnenblick, Moshe ^d,e   Breuer, Gabriel S ^d,e  

^a HEBREW UNIVERSITY   (Israel)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MEIR MEDICAL CENTER   (Israel)

^d SHAARE ZEDEK MEDICAL CENTER   (Israel)

^e BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Corticosteroids; Outcome; Polymyalgia rheumatica; Temporal arteritis

Indexed keywords

HEMOGLOBIN; PREDNISONE; STEROID;

AGED; ANEMIA; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG UTILIZATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FEVER; GIANT CELL ARTERITIS; HUMAN; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THROMBOCYTOSIS; TREATMENT RESPONSE;

ADRENAL CORTEX HORMONES; AGED; AGED, 80 AND OVER; COHORT STUDIES; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; GIANT CELL ARTERITIS; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; POLYMYALGIA RHEUMATICA; RETROSPECTIVE STUDIES;

EID: 52049105408     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. PIPITONE N, BOIARDI L, BAJOCCHI G. SALVARANI C: Long-term Outcome of giant cell arteritis. Clin Exp Rheumatol 2006; 24 (Suppl. 41): S65-70.
2. PROVEN A, GABRIEL SE, ORCES C, O'FALLON WM, HUNDER GG: Glucocorticoid therapy in giant cell arteritis: Duration and adverse outcome. Arthritis Rheum 2003; 49: 703-8.
3. NESHER G, RUBINOW A, SONNENBLICK M: Efficacy and adverse effects of different corticosteroid dose regimens in temporal arteritis. A retrospective study. Clin Exp Rheumatol 1997; 15: 303-6.
4. CID M, FONT C, ORISTRELL J et al.: Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. Arthritis Rheum 1998: 41: 26-32.
5. LIOZON E, BOUTROS-TONI F, LY K, LOUSTAUD-RATTI V, SORIA P, VIDAL E: Silent, or masked, giant cell arteritis is associated with a strong inflammatory response and a benign short term course. J Rheumatol 2003: 30: 1272-6.
6. NESHER G, BERKUN Y, MATES M et al.: Risk factors for cranial ischemic complications in giant cell arteritis. Medicine 2004; 83: 114-22.
7. HERNANDEZ-RODRIGUEZ J, GARCIA-MARTINEZ A, CASADEMONT J et al.: A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant cell arteritis. Arthritis Rheum 2002; 47: 29-35.
8. HERNANDEZ-RODRIGUEZ J, SEGARRA M, VILARDELL C et al.: Tissue production of pro-inflammatory cytokines (IL-1 beta, TNF alpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant cell arteritis. Rheumatology 2004; 43: 294-301.
9. GONZALEZ-GAY MA, GARCIA-PORRUA C, AMOR-DORADO JC, LLORCA J: Fever in biopsy-proven giant cell arteritis: Clinical implications in a defined population. Arthritis Rheum 2004; 51: 652-5.
10. HAYREH SS, PODHAJSKY PA, ZIMMERMAN B: Ocular manifestations of giant cell arteritis. Am J Ophthalmol 1998; 125: 509-20.
11. GONZALEZ-GAY MA, LOPEZ-DIAZ MJ, BARROS S et al.: Giant cell arteritis: Laboratory tests at the time of diagnosis in a series of 240 patients. Medicine 2005: 84; 277-90
12. HUNDER GG, BLOCH DA, MICHEL BA et al.: The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990; 33: 1122-8.
13. HACHULA E, BOIVIN V, PASTUREL-MICHON U et al.: Prognostic factors and long-term evolution in a cohort of 133 patients with giant cell arteritis. Clin Exp Rheumatol 2001; 19: 171-6.
14. WEYAND CM, FULBRIGHT JW, EVANS JM, HUNDER GG, GORONZY JJ: Corticosteroid requirements in polymyalgia rheumatica. Arch Intern Med 1999; 159: 577-84.
15. GONZALEZ-GAY MA, GARCIA-PORRUA C, PINEIRO A, PEGO-REIGOSA R, LLORCA J, HUNDER GG:AOrtic aneurysm and dissection in patients with biopsy-proven giant cell arteritis from Northwestern Spain. Medicine 2004; 83: 335-41.
16. HERNANDEZ-RODRIGUEZ J, SEGARRA M, VILARDELL C et al.: Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis. Angiogenic activity of interleukin-6 as a potential protective mechanism. Circulation 2003; 107: 2428-34.
17. TER BORG EJ, HAANEN HC, SELDENRIJK CA: Relationship between histological subtypes and clinical characteristics at presentation and outcome in biopsy-proven temporal arteritis. Identification of a relatively benign subgroup. Clin Rheumatol 2007; 26: 529-32.
18. PETURSDOTTIR V, JOHANSSON H, NORDBORG E, NORDBORG C: The epidemiology of biopsy-positive giant cell arteritis: Special reference to cyclic fluctuations. Rhematology, 1999; 38: 1208-12.
19. SMEETH L,. COOK C, HALL AJ: Incidence of polymyalgia rheumatica and temporal arteritis in the United Kingdom, 1990 to 2001. Ann Rheum Dis 2006; 65: 1093-8.
20. RAYNAULD JP, BLOCH DA, FRIES JF: Seasonal variation in the onset of Wegener's granulomatosis, polyarteritis nodosa and giant cell arteritis. J Rheumatol 1993; 20: 1524-6.
21. GONZÁLEZ-GAY, MA, GARCÍA-PORRUA, C, RIVAS MJ, RODRIGUEZ-LEDO P, LLORCA J: Epidemiology of biopsy proven giant cell arteritis in northwestern Spain: Trend over an 18-year period. Ann Rheum Dis 2001; 60: 367-71.
22. BAS-LANDO M, BREUER GS, BERKUN Y, MATES M, SONNENBLICK M, NESHER G: The incidence of giant cell arteritis in Jerusalem over a 25-year period: annual and seasonal fluctuations. Clin Exp Rheumatol 2007; 25 (Suppl. 44): 15-7.
23. GONZÁLEZ-GAY, MA, GARCÍA-PORRUA, C, VASQUEZ-CARUNCO M: Polymyalgia rheumatica in biopsy proven giant cell arteritis does not constitute a different subset but differs from isolated polymyalgia rheumatica. J Rheumatol 1998; 25: 1750-5.